welcome
Insider Trading & Hedge Fund Data, and Investment Newsletter From Insider Monkey

Insider Trading & Hedge Fund Data, and Investment Newsletter From Insider Monkey

Health

Health

William Blair Reaffirms Outperform Rating on Rocket Pharma Despite Trial Setback

Insider Trading & Hedge Fund Data, and Investment Newsletter From Insider Monkey
Summary
Nutrition label

76% Informative

Sami Corwin maintained his Outperform rating on Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) on May 27 with no price target, despite the company's recent difficulties.

The biotechnology company's trial for the gene therapy medicine RP-A501 was clinically halted and a patient tragically passed away.

RCKT stock's price tanking by around 80% year-to-date .

VR Score

74

Informative language

74

Neutral language

0

Article tone

formal

Language

English

Language complexity

60

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

short-lived

Source diversity

1

Affiliate links

no affiliate links